Acquiring Company
SERB Pharmaceuticals
Acquired Company
Y-MAbs
Paris
New YorkManufacturingBiotechnologyHealth CareBiotechnologyDescription
SERB Pharmaceuticals has completed its acquisition of Y-mAbs Therapeutics, enhancing its Rare Oncology portfolio. The acquisition allows SERB to utilize Y-mAbs' expertise in oncology and expand partnerships in the US oncology community. Y-mAbs has become a wholly owned subsidiary of SERB following the successful tender offer. The acquisition signals a commitment to advancing treatments for rare and pediatric cancers.
Who to call at SERB Pharmaceuticals, and when
When SERB Pharmaceuticals changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day SERB Pharmaceuticals raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at SERB Pharmaceuticals, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at SERB Pharmaceuticals. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment SERB Pharmaceuticals makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Y-MAbs?
Y-MAbs was acquired by SERB Pharmaceuticals, based in Paris. The deal was reported on September 16, 2025. SERB is a global specialty pharmaceutical company with a growing portfolio of medicines for emergency care and rare diseases. SERB Pharmaceuticals is privately held and operates in Manufacturing.
When did SERB Pharmaceuticals acquire Y-MAbs?
SERB Pharmaceuticals's acquisition of Y-MAbs was reported on September 16, 2025. SERB Pharmaceuticals has completed its acquisition of Y-mAbs Therapeutics, enhancing its Rare Oncology portfolio. The acquisition allows SERB to utilize Y-mAbs' expertise in oncology and expand partnerships in the US oncology community. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Y-MAbs do?
Y-MAbs is focused on developing innovative oncology treatments targeting cancer and associated disorders. The company works on advanced therapeutics and has several products in different stages of development. It is privately held, operating in Biotechnology, and is based in New York.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.